Sobi and Horizon make 5 year commitment to distribute their drugs in Europe

By Dani Bancroft

- Last updated on GMT

iStock/petinovs
iStock/petinovs

Related tags Pharmacology Europe

Swedish Orphan Biovitrum AB (Sobi) and Horizon Pharma plc have teamed up for a 5-year deal to distribute urea cycle disorder drugs Ravicti and Ammonaps in Europe and the Middle East.

Sobi, a biopharmaceutical specialist in rare diseases, will have exclusive marketing, sales and rights and distribution rights for both small molecules until the end of December, 2021.

Alan Raffensperger, Sobi COO, said in a statement: “This distribution agreement will allow us to leverage our existing expertise and extensive experience within the area of UCDs.”

Target markets

Ravicti is currently distributed within certain Middle East countries, and Horizon plans to distribute the drug in European countries including the UK, France, Germany and Spain.

Ammonaps will be distributed in both these European countries and the same regions in the Middle East.

“We believe that Sobi's current distribution of Ammonaps uniquely qualifies it to effectively provide Ravicti to people living with UCDs in European markets,” ​said Francoise de Craecker–group vice president and general manager at Horizon–in a statement.

Urea cycle disorders

Ravicti is Horizon’s oral formulation of glycerol phenylbutyerate, developed for management of urea cycle disorder drugs (UCDs) alongside restriction of dietary proteins and treatment of acute hyperannoemia (excess ammonia).

Ammonaps is a tablet form of sodium phenylbutyrate developed for patients​ of all ages with neonatal-onset of UCDs (i.e. complete enzyme deficiency) by Sobi.

The drug is also indicated for late-onset patients with a risk of brain swelling caused by excess ammonia.

Sobi plans to launch Ravicti within Europe in 2017.

Related news

Related products

show more

Ultra Low Temperature Packaging solutions

Ultra Low Temperature Packaging solutions

Content provided by Almac Group | 12-Feb-2024 | Case Study

Advanced Therapy Medicinal Products (ATMPs) offer ground-breaking opportunities for treating injuries and disease, in particular for cases of severe, untreatable...

Unlock potential in buffer preparation

Unlock potential in buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Sep-2023 | Infographic

Consider how the right partner can help you scale faster, mitigate risks, and optimize resources.

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 14-Aug-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Follow us

Webinars